- Radiation therapy with or without combination chemotherapy or Pazopanib Hydrochloride before surgery in treating patients with soft tissue sarcomas that can be removed by surgery.
- Anti-PD1 Antibody Pembrolizumab (MK-3475) – KEYTRUDA
- The Sarcoma Alliance for Research through Collaboration (SARC) entered into a Phase II study of Keytruda with Merck Pharmaceutical Company, in collaboration with Dohme Corp., for advanced sarcomas, bone sarcomas, and soft tissue sarcomas – including leiomyosarcoma.
- The study continues with no further recruitment of participants at this time. The estimated completion date for final data collection for “primary outcome” measure is December 2016.
- The clinical, research, and social value of autopsy after any cancer death: A perspective from the Children’s Oncology Group Soft Tissue Sarcoma Committee
- Global task force tackles problem of untreatable cancers and disease relapse
- Broad targeting of angiogenesis for cancer prevention and therapy
- Yondelis (Trabectedin) Approved by the FDA for Leiomyosarcoma and Liposarcoma.
- The chemotherapy drug Trabectedin (Yondelis) was approved by the FDA to treat Leiomyosarcoma and Liposarcoma, deemed unresectable, yet previously treated with chemotherapy that contained the drug anthracycline.
- Yondelis was evaluated in clinical studies involving 518 patients. Those who were given Yondelis had a cancer progression that stopped for an average of 4.2 months, compared to an average of 1.5 months for the patient group members who took another anti-cancer drug.
- The most common side effects of Yondelis include nausea, fatigue, vomiting, diarrhea, constipation, loss of appetite, shortness of breath, headache, and tissue swelling. The drug’s label has an additional list of side effects as well. Yondelis is marketed by Janssen Products.